Thank you as much as I do not like the fat intake and possible problem with rash , the success rate is higher and tx time is lower so I was originally leaning towards Vic but the shorter tx time and less pills is looking pretty good at this stage . At least the option is available , for yourself I can understantand why you chose Vic .So glad to her you are UND you will make it .
Express your concerns and med history carefully w/hep doc. I'm glad I'm on Vic b/c I'm prone to excema and had rash issues due to riba. My present anemia is holding around 9-9.5. The bad news is that I'll be opn Vic longer than 12 weeks-the pills get tougher to swallow as the day progresses. The great news is I'm UND for wks 8 and 12 vl's.
Thank you Hector, and yes , I will take your advice it has been a while since I last posted .Thanks.
All prior threads you started are automatically stored in your watch list on your home page, really easy to find.
I'd like to suggest making a file to keep your information in.
You can do it on your computer or write things down and keep them filed.
I know its often hard to remember.
I cut and paste items all the time.
Then I can refer to my files to refresh my memory.
"Normally it is based on prior tx history. Incivek is the one for relapsers, non-responders or second or more tx's."
Where did that come from? Never heard that before. Many prior relapsers here that are SVR now.
Thanks for reminding me I reread it .
Some doctors may feel one drug is better than the other for various reasons. Some doctors use both drugs and they may decide to use one over the other depending on other health issues a person has and/or the side effects. Or the patient may prefer one over the other. Some doctors prefer one over the other and use only one of them. I know my doctor uses only Incivek.
Normally it is based on prior tx history. Incivek is the one for relapsers, non-responders or second or more tx's. That said, you may be able to choose your weapon depending on the doctor and your circumstances. good luck
"Which New Hepatitis C Drug do MDs Prefer?:
Incivek (telaprevir) vs. Victrelis (boceprevir)
http://hepatitiscnewdrugs.blogspot.com/2011/10/hey-doc-victrelis-boceprevir-or-incivek.html
Background:
Physicians ( 65 Gastroenterologist & 36 Infectious Disease & 6 others) were provided three recent news articles about Incivek (telaprevir) and Victrelis (boceprevir) and asked to compare these two new hepatitis C drugs:
* Gauge the awareness level and use of these new treatments
* Evaluate the "real-life" efficacy of each drug with current patients
* Predict which product will become the standard of care
Executive Summary
* Overall, more than 90% of surveyed physicians confirmed that they are aware of the approval and availability of both Incivek and Victrelis.
* 21% of physicians are only prescribing Incivek compared to 8% who are only writing Victrelis.
* Efficacy was listed as the top strength for both drugs. MDs identified the following individual strengths for each drug:
* Incivek: Often Shorter Duration of Treatment Plan, Simple Regimen/Fewer Pills. Best for prior Null Responders. More potential for 24 weeks of treatment. Less severe anemia.
* Victrelis: Less Frequent Rash, Tolerability
34% of physicians tapped Incivek to become Standard of Care (SOC)
Percentage of MDs Prescribing Each Drug
Over half of physicians are already prescribing both new drugs
Of those physicians who are only prescribing one drug, 21% are prescribing Incivek; while only 8% are writing Victrelis
Physicians Identified Top Strengths of Incivek
MD respondents selected efficacy as top strength of Incivek
Strengths listed for Incivek over Victrelis included: Often Shorter Duration of Tx and Simple Regimen/Fewer Pills
Physicians Identified Top Strengths of Victrelis
MD respondents selected efficacy as top strength of Victrelis
Strengths listed for Victrelis over Incivek included: Less Frequent Rash and Tolerability
Patients Response to Both Drugs
Physicians asked for more data from Victrelis on co-infected patients as well as more data from both drugs on efficacy in HIV+ patients
Physicians Weigh in on Standard of Care
34% of physicians tapped Incivek to become Standard of Care
55% of physicians were unsure if either of these products would be the next Standard of Care"
Hector